Mehta, C. R., Michelson, G., Salganik, M., Feaster, J., Allen, R., Cahill, A. L., … Feldman, E. J. (2011). Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia. In Journal of Clinical Oncology (Vol. 29, pp. TPS201–TPS201). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2011.29.15_suppl.tps201

Mehta, C. R., G. Michelson, M. Salganik, J. Feaster, R. Allen, A. L. Cahill, J. A. Fox, et al. “Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.” In Journal of Clinical Oncology, 29:TPS201–TPS201. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.tps201.

Mehta CR, Michelson G, Salganik M, Feaster J, Allen R, Cahill AL, et al. Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. TPS201–TPS201.

Mehta, C. R., et al. “Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2011, pp. TPS201–TPS201. Crossref, doi:10.1200/jco.2011.29.15_suppl.tps201.

Mehta CR, Michelson G, Salganik M, Feaster J, Allen R, Cahill AL, Fox JA, Ketchum SB, Ravandi F, Erba HP, Schiller GJ, Stuart RK, Vey N, Feldman EJ. Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. TPS201–TPS201.